Senior Business Development Manager
Keywords Studios- Full Time
- Senior (5 to 8 years)
Asimov is seeking a (Senior) Business Development Manager to join its fast-growing Commercial team. This role focuses on taking ownership of one of Asimov's core territories (Mid-Atlantic or Southwest U.S.). It is a senior individual contributor position emphasizing leadership, autonomy, and strategic ownership without a traditional management hierarchy. While there are no direct reports initially, success is measured by individual performance and the ability to collaborate across teams to achieve collective goals.
Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We are developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics.
We are looking for a hands-on, results-driven professional who thrives in a fast-paced, dynamic environment and is eager to make an immediate impact on Asimov’s commercial growth and strategy.
Asimov is fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Joining our team means growing with a constantly evolving organization and pushing the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.
Synthetic biology solutions for biopharmaceuticals
Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.